KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (Diluted Average) (2020 - 2025)

Adaptive Biotechnologies' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $151.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 3.14% year-over-year to $151.7 million; the TTM value through Dec 2025 reached $151.7 million, up 3.14%, while the annual FY2025 figure was $151.7 million, 3.14% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $151.7 million at Adaptive Biotechnologies, roughly flat from $151.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $152.1 million in Q2 2025 and bottomed at $139.7 million in Q2 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $144.4 million (2023), against an average of $145.0 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) increased 6.96% in 2021 before it increased 1.28% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $140.4 million in 2021, then grew by 1.54% to $142.5 million in 2022, then grew by 1.31% to $144.4 million in 2023, then increased by 1.88% to $147.1 million in 2024, then rose by 3.14% to $151.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Shares Outstanding (Diluted Average) are $151.7 million (Q4 2025), $151.2 million (Q3 2025), and $152.1 million (Q2 2025).